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Abstract: Abnormal levels of DNA methylation and/or histone modifications are observed in patients with a wide variety 
of chronic diseases. Methylation of lysines within histone tails is a key modification that contributes to increased gene ex-
pression or repression depending on the specific residue and degree of methylation, which is in turn controlled by the in-
terplay of lysine methyl transferases and demethylases. Drugs that target these and other enzymes controlling chromatin 
modifications can modulate the expression of clusters of genes, potentially offering higher therapeutic efficacy than clas-
sical agents acting on downstream biochemical pathways that are susceptible to degeneracy. Lysine demethylases, first 
discovered in 2004, are the subject of increasing interest as therapeutic targets. This review provides an overview of recent 
findings implicating lysine demethylases in a range of therapeutic areas including oncology, immunoinflammation, meta-
bolic disorders, neuroscience, virology and regenerative medicine, together with a summary of recent advances in struc-
tural biology and small molecule inhibitor discovery, supporting the tractability of the protein family for the development 
of selective druglike inhibitors.  
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INTRODUCTION 
  Although every cell within an organism contains the 
same genetic information, the pattern of genes that are acti-
vated and silenced in a given cell is highly dependent on its 
differentiation state and environment. Individual cellular 
gene expression patterns are mediated by at least four dis-
tinct but interrelated molecular processes: DNA methylation, 
histone post-translational modifications, non-coding RNAs, 
and nucleosome positioning [1]. Together, these four proc-
esses form a complex network, sometimes referred to as an 
epigenetic landscape or code [2], that provides a mechanism 
for “potentially heritable changes in gene expression that do 
not involve changes in DNA sequence” [3]. A large body of 
epidemiological and molecular evidence has accumulated to 
demonstrate that early life experiences strongly impact on 
epigenetic modifications, leading to a working hypothesis for 
‘developmental plasticity’, by which cellular organisms 
adapt their structure and function in response to environ-
mental cues such as diet, drugs, hormones, toxins, stress and 
infections [4]. Epigenetic responses are most plastic during 
early life and then become increasingly irreversible, thereby 
imposing a memory effect that can modulate an individual’s 
phenotype and their susceptibility to disease. 
  The epigenetic code is characterized by a high degree of 
cross-talk between individual modifications (for an example 
see [5]), and varying degrees of plasticity. While DNA 
methylation constitutes a binary switching mechanism 
(methylation at or near gene promoters correlates with gene 
silencing and vice versa), histone modifications are highly  
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complex in terms of both the number of sites that can be 
modified, and in the variety of possible modifications [6]. 
Histones H2A, H2B, H3 and H4 are comprised of DNA-
binding cores, together with largely unstructured tails that 
project from the nucleosome particle. Both cores and tails 
are subject to post-translational modifications on the side 
chains of certain amino acid residues, including acetylation 
of lysine, methylation of lysine or arginine, phosphorylation 
of serine or threonine, SUMOylation, ubiquitination and 
ADP-ribosylation. These modifications occur at different 
sites simultaneously, leading to a bewildering array of possi-
ble combinations regulated by several hundred complemen-
tary enzymes and recognition domains that add or remove 
specific modifications or bind specifically to modified resi-
dues to recruit additional transcriptional regulators (Fig. 1). 
  Methylation at specific histone tail residues, in particular 
H3K4, is associated with actively transcribed gene loci, 
whereas methylation at other histone tail positions (H3K9, 
H3K27) generally leads to transcriptional silencing and het-
erochromatinisation. Dynamic regulation of lysine methyla-
tion and demethylation is effected by lysine methyltrans-
ferases (KMTs) and demethylases (KDMs) respectively, 
creating patterns of methylation marks that serve as binding 
sites for methyl binding domains (MBDs), which may form 
part of other histone-modifying enzymes or recruit protein 
complexes involved in transcriptional regulation. The known 
functions of individual methylation events are too complex 
to be described comprehensively here but have been re-
viewed in detail recently (see [7, 8]).  
LYSINE DEMETHYLASE PROTEIN FAMILIES 
  Lysine demethylases fall into two major classes defined 
by their structure and mechanism:  
1)  The LSD (lysine specific demethylase) family are 
homologues of the flavin-containing monoamine oxi-
dases, and use the co-factor flavin adenine dinucleo-Chemical Biology of Lysine Demethylases  Current Chemical Genomics, 2011, Volume 5    63 
tide (FAD) to oxidize methylated lysines to the corre-
sponding imine intermediate followed by hydrolysis 
to give the demethylated lysine and formaldehyde as 
byproduct (Fig. 2a) [9]. LSDs are incapable of de-
methylating trimethyllysine residues, because the 
quaternary ammonium group cannot form the requi-
site imine intermediate. To date two enzymes, LSD1 
and LSD2, have been discovered in this subfamily. 
2)  Jumonji-domain containing demethylases belong to a 
relatively large family of 2-oxoglutarate (2-OG) con-
taining oxygenases, which also includes HIF-prolyl 
hydroxylase. These enzymes use Fe(II) together with 
2-oxoglutarate to oxygenate methyl groups on methy-
lated lysines, generating the corresponding hy-
droxymethyl amine, which undergoes the same fate as 
in the LSD1 mechanism (Fig. 2b) [10, 11]. This 
mechanism allows for demethylation of all three pos-
sible methylation states of lysine residues.  
  The known FAD and 2-OG containing demethylases 
have been classified into several subfamilies, and a system-
atic KDM nomenclature system has been proposed: LSD1 
(KDM1); JARID1 (JMJD5); JMJD1 (KDM3); JMJD2A-E 
(KDM4); UTX/JMJD3 (KDM6A/B); FBXL11 (KDM2), 
JMJD5 (KDM8) [12]. 
SUBSTRATE SPECIFICITY 
  The sequence selectivity of demethylation within his-
tones has been established for many of the demethylases 
(Fig. 3) [13]. Demethylase catalytic domains have an intrin-
sic sequence selectivity, but this can be modulated by com-
plex formation. Hence, LSD1 has been shown to repress 
gene expression through the demethylation of H3K4Me1/2, 
while its association with the androgen receptor leads to en-
hanced transcription by demethylation of H3K9Me1/2 [14]. 
  Among the 2-OG dependent demethylases, individual 
enzymes show methylation state selectivity apparently 
driven by steric accommodation: trimethyl demethylases 
(e.g. JMJD2A) having larger methyllysine binding pockets 
than dimethyl demethylases (e.g. FBXL11, PHF8) [15, 16]. 
  In some cases, the sequence selectivity of demethylation 
is partly controlled by other domains within the enzymes, as 
recently described for PHF8 and KIAA1718 [16]. PHF8 con-
tains a PHD finger which binds to H3K4Me3, directing the 
catalytic domain towards H3K9Me2 and thereby increasing 
its activity and selectivity by ~100-fold; whilst for 
KIAA1718, PHD finger binding to H3K4Me3 directs the 
catalytic domain to preferentially demethylate H3K27Me2. 
The extent to which similar binding domain control occurs in 
the substrate selectivity of other demethylase subfamilies 
(for example JMJD2A-C enzymes which contain methyl-
lysine-binding tudor domains) remains to be explored. 
  As described in the introduction, a variety of modifica-
tions can co-exist on individual histone tails, creating a com-
plex system of cross-talk between the individual marks. In-
deed, the aptitude of methylated histone lysines to be 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Selected target sites of histone modifying enzymes (with kind permission from Springer Science+Business Media: Curr Top Behav 
Neurosci., Animal models of epigenetic regulation in neuropsychiatric disorders, vol. 7 (2011) pp281-322, Bountra C, Oppermann U, 
Heightman TD, Fig. 1). 
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Fig. (2). Mechanisms of lysine demethylation catalysed by a) FAD-dependent LSD1; b) 2-OG dependent jumonji domain containing   
demethylases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Human protein lysine demethylases and their target sites on histones [13]. 
demethylated is influenced by post-translational modifica-
tions at neighbouring residues: for example, phosphorylation 
of H3T11 by the kinase PRK1 has been shown to accelerate 
demethylation of H3K9Me3 by the demethylase JMJD2C 
[17]; in contrast, phosphorylation of H3S10 prevents 
demethylation of H3K9 by the JMJD2 demethylases [15]. 
DISEASE LINKS 
Cancer  
  Aberrations in levels of histone methylation are fre-
quently correlated with tumorigenesis, presumably resulting 
from an imbalance between histone methyltransferases and 
demethylases [1]. Common changes include loss of activat-
ing marks (H3K4Me3), loss of certain repressive marks 
(H4K20Me3), and gain of other repressive marks (H3K9Me3 
and H3K27Me3). Several demethylases are specifically im-
plicated in the pathogenesis of a variety of cancer types. 
Both LSD1 and JARID1B are overexpressed in prostate can-
cer, while LSD1 expression correlates with tumor recurrence 
during therapy [18]. LSD1 also demethylates p53, repressing 
p53-mediated transcriptional activation and inhibiting the 
role of p53 in promoting apoptosis [19]. LSD1 inhibition by 
treatment of colon cancer cells with the oligoamine inhibitor 
SL111144 led to increases in H3K4Me3, restoring expression 
of secreted frizzled-related proteins (SFRP) Wnt signaling 
pathway antagonist genes [20]. In neuroblastoma cells, 
siRNA–mediated knockdown of LSD1 decreased cellular 
growth, induced expression of differentiation-associated 
genes, and increased target gene–specific H3K4 methylation 
[21]. These effects were recapitulated by LSD1 inhibition 
using monoamine oxidase inhibitors, which further demon-
strated growth inhibition of neuroblastoma cells in vitro and 
reduced neuroblastoma xenograft growth in vivo. JARID1B 
and JMJD2C are overexpressed in breast and testis cancer 
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and esophageal squamous carcinoma [22], and RNAi inhibi-
tion of JMJD2C resulted in the inhibition of cell prolifera-
tion, which highlights this isoform as a potential therapeutic 
target [11]. Systematic sequencing of renal carcinomas has 
identified inactivating mutations in UTX and JARID1C [23]. 
Immuno-Inflammation 
  In addition to classical genetic susceptibilities, the etiolo-
gies of a variety of immuno-inflammatory diseases including 
asthma have been associated with early life programming of 
immune T-cell response, dendritic cell function, and macro-
phage activation mediated by epigenetic responses to envi-
ronmental cues [24]. Global mapping of histone H3K4Me3 
and H3K27Me3 has revealed specificity and plasticity in 
lineage fate determination of differentiating CD4+ T cells, 
suggesting that lineage fates might be manipulated by modu-
lators of lysine demethylase enzymes targeting these marks 
[25]. Importantly, expression of the demethylase JMJD3, 
which targets repressive H3K27Me3 marks, is induced in 
macrophages by the inflammatory transcription factor NFB 
in response to stimuli including LPS and the proinflamma-
tory cytokines IL4, IL13 and CCL17 [26]. Some 70% of 
lipopolysaccharide (LPS)-inducible genes have been shown 
to be JMJD3 targets, suggesting that JMJD3 is situated at a 
key position in inflammatory signalling cascades [27]. 
Metabolic Disorders & Diabetes 
  The histone H3K9 demethylase, JMJD1A has recently 
been associated with metabolic dysregulation: loss of func-
tion resulted in decreased expression of metabolically active 
genes (e.g. peroxisome proliferator–activated receptor- and 
medium-chain acyl-CoA dehydrogenase) in skeletal muscle, 
and impaired expression of cold-induced uncoupling protein 
1 in brown adipose tissue in rodents [28]. This study pro-
vides support for a causal relationship between epigenetic 
mechanisms and obesity (it has long been known that famine 
exposure in utero and in early infancy is linked to obesity in 
young men [29]). However, it is not evident that JMJD1A is 
a good target for the treatment of obesity, since the same 
authors have shown other essential roles for JMJD1A in 
mice, including in spermatogenesis [30]. 
  Although there are as yet no published links between 
demethylase function and the etiology of diabetes, data from 
several recent diabetes complication trials have shown that in 
patients who have returned to glycemic control for over 5 
years, altered gene expression profiles persist that are linked 
to eventual complications including blindness, end-stage 
renal failure, and peripheral neuropathy [31]. This “hyper-
glycemic memory” has been attributed to changes in epige-
netic information including H3K4 and H3K9 modifications 
at the NFB-p65 promoter mediated by the histone methyl-
transferases (Set7 and SuV39h1) and the lysine-specific de-
methylase (LSD1). 
Neuroscience 
  Epigenetic abnormalities, which may be introduced dur-
ing embryogenesis, puberty, or adulthood, have been noted 
in several psychiatric disorders, including drug addiction, 
depression and schizophrenia [32]. In rats, acute stress has 
been shown to increase levels of the repressive H3K9Me3 
mark in the dentate gyrus and hippocampal CA1 region, 
while reducing levels of H3K27Me3 in the same regions, 
with no effect on levels of H3K4Me3  [33]. Interestingly, 
treatment with the anxiolytic SSRI antidepressant fluoxetine 
reversed the decrease in dentate gyrus H3K9Me3, but had no 
effect on the other marks. Mutations of the human H3K9/27 
demethylase PHF8 cluster within its JmjC encoding exons, 
and are linked to mental retardation (MR) and a cleft 
lip/palate phenotype [34]. 
Antiviral 
  Invading viral pathogens that depend upon the host cell's 
transcriptional machinery are also subject to the regulatory 
impact of histone modifications, and this has been specifi-
cally demonstrated for LSD1: depletion or inhibition of its 
activity with monoamine oxidase inhibitors (MAOIs) results 
in blockade of herpes simplex virus (HSV) and varicella 
zoster virus (VZV) gene expression [35]. 
Regenerative Medicine 
  Epigenetic landscapes are implicitly involved in the dif-
ferentiation of stem cells [36, 37], and modulation of the 
enzymes mediating epigenetic marks might be expected to 
allow manipulation of stem cell fates, an approach of great 
interest in regenerative medicine. Among the histone modi-
fying enzymes, evidence is emerging to implicate lysine de-
methylases in maintenance or progression of stem cell states. 
The H3K9 demethylases JMJD1a and JMJD2c regulate self-
renewal in embryonic stem cells: depletion of either enzyme 
using shRNA results in progression to ES cell differentia-
tion, accompanied by a reduction in the expression of ES 
cell-specific genes and an induction of lineage marker genes 
[38]. Progression of neural stem cells to neurons is regulated 
by the nuclear receptor co-repressors N-CoR and SMRT (aka 
N-CoR2), which repress expression of the H3K27 demethy-
lase JMJD3, preventing activation of specific components of 
the neurogenic program [39]. The H3K4 demethylase LSD1 
is recruited by nuclear receptor TLX, an essential neural 
stem cell regulator, to the promoters of TLX target genes to 
repress the expression of these genes, which are known regu-
lators of cell proliferation: inhibition or knockdown of LSD1 
was reported to dramatically reduce neural stem cell prolif-
eration [40]. 
STRUCTURAL BIOLOGY 
  Both classes of lysine demethylase are well characterized 
structurally, including substrate complexes that aid under-
standing of their mechanisms: a selection of representative 
structures are summarized in Table 1. The structure of the 
LSD1-CoREST (corepressor for element-1-silencing tran-
scription factor) complex containing a covalent adduct be-
tween FAD and a suicide substrate based on the target 
H3K4Me2 histone peptide (Fig. 4) shows positioning of the 
lysine methyl groups in suitable proximity for FAD-
mediated hydride abstraction to form the iminium intermedi-
ate, as per Fig. (2a) [41]. The structure also provides an ex-
planation for the specificity of demethylation at H3K4: the 
terminal amino group of Ala1 inserts into an anionic pocket 
comprized of Asn, Trp, and two Asp residues, a binding 
mode not possible with substrates with more than three resi-
dues on the N-terminal side of the target methyllysine. 
  Crystal structures for several members of the 2-OG-
dependent histone demethylase family show a common dou-
ble-stranded  -helix (DSBH) fold typical of 2-OG 66    Current Chemical Genomics, 2011, Volume 5  Tom D. Heightman 
Table 1.  Selected High-Resolution Crystal Structures of Human Lysine Demethylases 
Demethylase Domains  in  structure  Ligands  PDB  code  References 
JMJD2A JMJ  H3K9Me3/2/1, NOG  2OS2, 2OT7, 2OX0  [15] 
 JMJ 2,4-PDCA  2VD7  - 
 JMJ Oxalyltyrosine  derivative  2WWJ  [48] 
 JMJ 5C-8HQ  3NJY  [51] 
 Tandem  Tudor  H3K4Me3 2GFA  [52] 
 Tandem  Tudor  H4K20Me3 2QQS  [53] 
JMJD2C JMJ  NOG  2XML  - 
 Tudor  -  2XDP  - 
JMJD2D JMJ  NOG  3DXU  - 
JMJD3 JMJ  8HQ-5CA  2XXZ  - 
FBXL11 
(hJHDM1A) 
JMJ 2-OG  2YU1  - 
PHF8 JMJ  H3K4Me3K9Me2, NOG  3KV4  [16] 
KIAA1718 JMJ  NOG 3KV5  [16] 
LSD1  LSD1-CoREST  FAD + H3K4Me2 suicide substrate  2UXN  [41] 
 LSD1-CoREST  FAD + trans-2-Phenylcyclo-
propylamine 
3XAF, 3XAG, 3XAH, 
3XAJ, 3XAQ, 3XAS 
[54] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). left: X-ray crystal structure of LSD1 (blue) in complex with FAD-H3K4Me2-suicide substrate peptide (red). H3KMe3 peptide (red). 
right: close-up view of active site, showing positioning of the lysine methyl groups in close proximity for FAD-mediated hydride abstraction 
to form the iminium intermediate, as per Fig. (2a). 
oxygenases, which supports the common Fe(II)-binding fa-
cial triad of a single glutamate or aspartate and two histidine 
residues (Fig. 5). The cofactor 2-OG coordinates to Fe(II) in 
a bidentate manner through its carboxylate and ketone moie-
ties at C-1 and C-2, while the C-5 carboxylate is tethered by 
forming a salt bridge to a lysine residue at the other end of 
the cofactor binding site. X-ray structures of a series of com-
plexes between the JMJD2A demethylase and histone H3 
peptides differentially methylated at K9 showed that the pep-
tide chain lies across a shallow groove, presenting the 
methylated lysine side-chain into a relatively large cavity 
bounded by several aromatic residues, with the methylamino 
group sufficiently close to the Fe(II) for hydroxylation [15]. 
These structures also provide a rationale for the sequence 
preference of JMJD2 enzymes for methylation at H3K9: the 
preferred peptide conformation is stabilized by an in-
tramolecular H-bond between the backbone carbonyl of K9 
and the side chain hydroxyl group of S10, which is not pos-
sible with other flanking residues or upon phosphorylation of 
S10 (vide infra). Chemical Biology of Lysine Demethylases  Current Chemical Genomics, 2011, Volume 5    67 
INHIBITOR DESIGN 
  The druggability of both FAD-dependent and 2-OG-
dependent demethylases is supported by the recent develop-
ment of low micromolar inhibitors of members of both these 
protein families, a selection of which are highlighted in Ta-
ble  2. Small molecule LSD1 inhibitors include the non-
specific monoamine oxidase inhibitors, tranylcypromine [42] 
and pargyline [14], and thalidomide derivatives pomalido-
mide and lenalidomide [43]. These inhibitors show effects 
on histone H3K9 and H3K4 methylation levels in cells, me-
diated by inhibition of LSD1-catalysed demethylation. The 
inhibition by tranylcypromine derivatives has been shown to 
occur by formation of a covalent adduct with the FAD cofac-
tor [42]. Structure-guided design has led to substituted vari-
ants of tranylcypromine with potency enhancements of over 
100-fold, exemplified by the homoserine derivative Com-
pound 2, which is selective against MAO-A and B, and 
shows recovery of H3K4Me2 levels in HEK293T cells and 
growth inhibition against human cancer cell lines at concen-
trations ranging from 6-67 μM [44]. The simpler analogue 
S2101, which shows a Ki of 0.6 μM, was able to increase 
levels of H3K4Me2 in HEK293T cells at concentrations as 
low as 1 μM [45]. The co-structure of a related analogue 
S1201 with LSD1 confirms the covalent adduct formed with 
FAD (Fig. 6), and shows how the additional benzyloxy sub-
stituent occupies an additional active site cavity, proposed to 
enhance the potency for LSD1 and selectivity over MAOs 
for this inhibitor series. Polyamines such as PG-11150 have 
also been shown to be inhibitors of LSD1 in vitro; in cells, 
these compounds show increased H3K4Me levels and, as 
described above, elicit reexpression of aberrantly silenced 
genes in human colon cancer cells [20]. 
  JMJD2 demethylases, the most studied subfamily of 2-
OG dependent enzymes, are inhibited by co-factor analogues 
including N-oxalylamino acids such as N-oxalyl glycine, 
which coordinates to the catalytic Fe(II) in a similar orienta-
tion to 2-OG itself, via its carboxylate and amide carbonyl 
moieties at C-1 and C-2 [46, 47]. Across the JMJD2A, 
FBXL11 and PHF8 enzymes the C-5 carboxylate of NOG is 
tethered by forming a salt bridge to a lysine residue at the 
other end of the cofactor binding site (Table 2, Fig. 7a-c). 
The similarity in the binding mode suggests that targeting 2-
OG analogues might bring a significant challenge in achiev-
ing selectivity; however, these enzymes display significant 
differences in active site structures that might be exploited in 
selective inhibitor design, and indeed the FBXL11/2-OG 
complex structure indicates a degree of plasticity in iron co-
ordination geometry as compared with JMJD2A and PHF8. 
Recently, the protein crystal structure of JMJD2A was used 
with a dynamic combinatorial chemistry approach to derive a 
series of substituted oxalyltyrosines that exploit a subpocket 
of this enzyme to improve potency into the single-digit mi-
cromolar range and enhance the selectivity over the 2-OG-
dependent prolyl hydroxylase PHD2 (Table 2, Fig. 7d) [48]. 
Interestingly, 2,4-pyridine dicarboxylate is a relatively potent 
inhibitor with high ligand efficiency (Table 2); this inhibitor 
mimics 2-OG but adopts an alternative iron coordination 
geometry whilst maintaining polar interactions between the 
4-carboxyl group and the active site lysine residue (Fig. 7e) 
[46]. Fragment growing of 2,4-PDCA generated the related 
bipyridyl template (Table 2). Other inhibitor chemotypes that 
are also presumed to bind to the active site Fe(II) include 
catechols, hydroxamic acids (including the clinically used 
HDAC inhibitor SAHA/Vorinostat), and TCA cycle inter-
mediates, such as succinate and fumarate) [46, 49].  
  A series of N-propionyl hydroxamic acids were recently 
designed to incorporate a methyllysine mimetic in addition 
to their 2-OG mimetic features [50]. The most active ana-
logue, Compound 8, showed low micromolar inhibition of 
JMJD2A/C with selectivity over prolyl hydroxylases PHD1 
and 2 (Table 2); interestingly, ester prodrugs of this com-
pound showed no effects on human cancer cells, but showed 
growth inhibition in combination with LSD1 inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). (Left) X-ray crystal structure of JMJD2A (blue) in complex with NOG (2-OG cofactor isostere) and a histone H3KMe3 peptide 
(red). (Right) Close-up view of active site: the Fe(II)-is complexed by a facial triad of a single glutamate or aspartate and two histidine resi-
dues, and the methylated lysine side-chain inserts into a relatively large cavity bounded by several aromatic residues, with the methylamino 
group positioned close to the Fe(II) for hydroxylation. 
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Table 2.  Examples of Small Molecule Lysine Demethylase Inhibitors 
Example  Structure  Activity References 
Tranylcypromine 
NH2
 
LSD1: Ki 357 μM [42] 
Compound 2 
NH2
O N H
O N
H
O Ph
Ph
 
LSD1: Ki 1.9μM 
MAO-A: Ki 290μM 
MAO-B: Ki >1000 μM 
[44] 
S2101 
NH2
O
F F
 
LSD1: Ki 0.6μM 
MAO-A: Ki110μM 
MAO-B: Ki17 μM 
[45] 
PG-11150  N
H
N
H
 
N
H
N
H
 
4
4
 
LSD1: IC50 5 μM [20] 
N-Oxalylglycine 
O
N
H
HO2C CO2H
 
JMJD2E: IC50 78 μM [46,  47] 
N-Oxalyltyrosine derivative 
O
N
H HO2C
CO2H O
S
O
O  
JMJD2E: IC50 5.4 μM [48] 
Vorinostat 
N
H
O
OH N
H
O
 
JMJD2E: IC50 14 μM [46] 
2,4-PDCA 
N
HO2C CO2H
 
JMJD2E: IC50 1.4 μM [46] 
Bipyridyl derivative 
N
HO2C
N
CO2H
 
JMJD2E: IC50 6.6 μM [46] 
Compound 8 
N
OH
O
N
O
OH
 
JMJD2A: IC50 3 μM 
JMJD2C: IC50 1 μM 
PHD1, 2: IC50>100μM 
[50] 
SID 85736331 
N
OH
CO2H
 
JMJD2A, E: IC50 2 μM 
FIH: IC50 14 μM 
PHD2: IC50 20 μM 
[51] 
 
  A functional high-throughput screen of JMJD2E identi-
fied the 8-hydroxyquinoline template, which coordinates the 
catalytic Fe(II) via the hydroxy group and pyridyl nitrogen 
[51]. A carboxylic acid group was added to mimic the distal 
carboxylate of 2-OG that interacts with the active site lysine, 
resulting in the micromolar inhibitor SID85736331 (Table 2, 
Fig. 7f). The methyl ester of this compound showed reversal 
of H3K9Me3 depletion in JMJD2A-overexpressing cells, as 
measured by immunofluorescence. 
OUTLOOK 
  The recent explosion in research into the roles of histone 
modifying enzymes in healthy and diseased cell function has 
provided a strong impetus for new drug target discovery. 
While it is clear that many of these enzymes are likely to be 
important for normal healthy function, the recent approval of 
epigenetic modulators such as HDAC inhibitors for cancer 
treatment demonstrates the potential for therapeutic benefit 
with acceptable safety and tolerability. Chemical Biology of Lysine Demethylases  Current Chemical Genomics, 2011, Volume 5    69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). X-ray crystal structure of LSD1active site containing FAD-S1201 suicide inhibitor covalent adduct. 
 
 
 
Fig. (7). X-ray crystallographic complexes of a) JMJD2A with NOG, b) FBXL11 with 2-OG, c) PHF8 with NOG, d-f) JMJD2A with an 
oxalyltyrosine derivative, 2,4-PDCA and 5-carboxy-8-hydroxyquinoline respectively. 
  Emerging data support a potential role for lysine demeth-
ylases as therapeutic targets in a variety of disease areas in-
cluding oncology, immunoinflammation, metabolic disor-
ders, neuroscience and virology. While tractability for 
screening and ligand discovery has been demonstrated for 
these enzymes, significant challenges remain, notably in 
identifying chemotypes that show potent and selective inhi-
bition of isoforms of interest whilst retaining physicochemi-
cal properties suitable for the intracellular site of action. Fur-
ther work to identify subtype-selective, cell penetrant inhibi-
tors will be essential in providing tools for chemical biology 
experiments to further characterize the roles of individual 
enzymes and their potential as therapeutic targets. 
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